COPD: Pipeline Assessment and Insights - ResearchAndMarkets.com

DUBLIN--()--The "COPD: Pipeline Assessment and Insights" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, highlights all the pipeline products in different phases of development for the disease including the suspended products and outlines in detail the drug profiles of key pipeline therapies in the disease area.

Pipeline Covered

  • NDA/BLA Filed
  • Phase III Pipeline
  • Phase II Pipeline
  • Phase I Pipeline
  • Preclinical Pipeline
  • Discovery Pipeline
  • Suspended and Terminated products
  • Pipeline analysis by Mechanism of Action
  • Pipeline Analysis by Novelty of Mechanism of Action

Disease Indication Overview: This section of the report gives the overview of COPD disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of COPD disease. Further details on the profile of COPD patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for COPD disease.

Pipeline Analysis by Phases, Mechanism of Action and Novelty of Mechanism of Action: This section of the report highlights and details the key products in development for COPD disease area. The section mentions the products in different phases of development including the NDA/BLA Filing phase, Phase III, Phase II, Phase I, Pre-Clinical phase and the Discovery phase. The section also details the products which have been suspended or terminated during the trial stages of development. The report in this section further highlights the different drugs in pipeline basis on Mechanism of Action of the drug and also on the basis of Novelty of Mechanism of Action of the drug.

Drugs Profile Overview: The report, in this section, details all the promising therapies, in COPD disease, in pipeline in different phases of development. The details of a promising drug in pipeline include a detailed overview about the drug in terms of its product details, mechanism of action, mode of administration etc. Further details include the research and development key milestones for the product, detailed information about the efficacy, safety and tolerability and dosage frequency and formulation of the drug. The report also tries to assess the potential clinical and potential commercial positioning of the drug based on the clinical attributes of the drug, trial design, innovator company's activities in the market and potential perceptions of the drug by physicians and knowledge experts while the drug is still in pipeline.

Companies Mentioned

  • Chugai Pharmaceutical
  • Roche
  • AC Immune
  • Eli Lilly
  • PDL BioPharma
  • NovaQuest Capital Management
  • Bayer
  • TauRx Pharmaceuticals
  • Forest Laboratories
  • Daiichi Sankyo
  • Merz
  • Neurobiological Technologies
  • Hanmi Pharmaceutical
  • Adamas Pharmaceuticals
  • Pfizer
  • Teikoku Seiyaku
  • Ono Pharmaceutical
  • Abbott Laboratories
  • BASF
  • Novartis
  • Esteve
  • LTS Gruppe
  • Johnson & Johnson
  • Shire
  • Takeda
  • Biogen
  • Neurimmune
  • MorphoSys
  • LifeArc
  • BioArctic
  • Astex Pharmaceuticals
  • AstraZeneca
  • Otsuka Holdings
  • Ipsen
  • Shionogi

For more information about this report visit https://www.researchandmarkets.com/research/pn2p84/copd_pipeline?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs